MA69153A1 - Méthodes de traitement d'une splénomégalie - Google Patents

Méthodes de traitement d'une splénomégalie

Info

Publication number
MA69153A1
MA69153A1 MA69153A MA69153A MA69153A1 MA 69153 A1 MA69153 A1 MA 69153A1 MA 69153 A MA69153 A MA 69153A MA 69153 A MA69153 A MA 69153A MA 69153 A1 MA69153 A1 MA 69153A1
Authority
MA
Morocco
Prior art keywords
methods
splenomegaly
treating
treating splenomegaly
therapeutic methods
Prior art date
Application number
MA69153A
Other languages
English (en)
Inventor
Wayne Philip Rothbaum
Original Assignee
Telios Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma, Inc. filed Critical Telios Pharma, Inc.
Publication of MA69153A1 publication Critical patent/MA69153A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des méthodes thérapeutiques et des compositions pharmaceutiques pour traiter une splénomégalie chez un sujet humain. Dans certains modes de réalisation, l'invention concerne des méthodes thérapeutiques de traitement d'une splénomégalie à l'aide d'un inhibiteur de BTK.
MA69153A 2020-01-08 2021-01-08 Méthodes de traitement d'une splénomégalie MA69153A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08

Publications (1)

Publication Number Publication Date
MA69153A1 true MA69153A1 (fr) 2025-07-31

Family

ID=76788747

Family Applications (3)

Application Number Title Priority Date Filing Date
MA57226A MA57226B1 (fr) 2020-01-08 2021-01-08 Méthodes de traitement d'une splénomégalie
MA63848A MA63848B1 (fr) 2020-01-08 2021-01-08 Méthodes de traitement d'une splénomégalie
MA69153A MA69153A1 (fr) 2020-01-08 2021-01-08 Méthodes de traitement d'une splénomégalie

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA57226A MA57226B1 (fr) 2020-01-08 2021-01-08 Méthodes de traitement d'une splénomégalie
MA63848A MA63848B1 (fr) 2020-01-08 2021-01-08 Méthodes de traitement d'une splénomégalie

Country Status (15)

Country Link
EP (2) EP3980069A4 (fr)
JP (2) JP7771064B2 (fr)
KR (1) KR20220130151A (fr)
CN (1) CN114423457A (fr)
AU (1) AU2021205484A1 (fr)
BR (1) BR112022013646A2 (fr)
CA (1) CA3164063A1 (fr)
CO (1) CO2022010592A2 (fr)
CR (1) CR20220374A (fr)
IL (1) IL294582A (fr)
JO (1) JOP20220168A1 (fr)
MA (3) MA57226B1 (fr)
MX (1) MX2022008490A (fr)
TN (1) TN2022000185A1 (fr)
WO (1) WO2021142257A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
TN2022000185A1 (en) * 2020-01-08 2024-04-01 Telios Pharma Inc Methods of treating splenomegaly
US20240293403A1 (en) * 2021-06-16 2024-09-05 Telios Pharma, Inc. Treatment of Symptoms Associated with Myeloproliferative Neoplasms
WO2023071973A1 (fr) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Composé bicyclique fusionné pour inhiber l'activité de la tyrosine kinase
WO2024041614A1 (fr) * 2022-08-25 2024-02-29 Beigene Switzerland Gmbh Formes solides comprenant du (s)-7-(1-acryloylpipéridin-4-yl)-2-(4-phénoxyphényl)-4,5,6, 7-tétrahydropyrazolo[1, 5-a]pyrimidine-3-carboxamide, et de l'acide oxalique, compositions et procédés d'utilisation associés

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024230A1 (fr) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Combinaisons thérapeutiques d'un inhibiteur de btk, d'un inhibiteur de pi3k, d'un inhibiteur de jak-2, et/ou d'un inhibiteur de bcl-2
WO2020192432A1 (fr) * 2019-03-27 2020-10-01 广州楹鼎生物科技有限公司 Procédé de décomposition catalytique d'une matière brute lignocellulosique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (fr) * 2013-10-16 2015-04-23 Izumi Raquel Inhibiteurs btk pour la mobilisation hématopoïétique
WO2015081127A2 (fr) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies pour le traitement de troubles myeloproliferatifs
WO2016054491A1 (fr) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
BR112020025881A2 (pt) * 2018-06-19 2021-03-23 Merck Patent Gmbh formas cristalinas de 1-(4-{[6-amino-5-(4-fenóxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal do mesmo e processos para obter as mesmas
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
TN2022000185A1 (en) * 2020-01-08 2024-04-01 Telios Pharma Inc Methods of treating splenomegaly

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024230A1 (fr) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Combinaisons thérapeutiques d'un inhibiteur de btk, d'un inhibiteur de pi3k, d'un inhibiteur de jak-2, et/ou d'un inhibiteur de bcl-2
WO2020192432A1 (fr) * 2019-03-27 2020-10-01 广州楹鼎生物科技有限公司 Procédé de décomposition catalytique d'une matière brute lignocellulosique

Also Published As

Publication number Publication date
MA57226A1 (fr) 2023-02-28
JP2023509968A (ja) 2023-03-10
CO2022010592A2 (es) 2022-10-31
EP3980069A4 (fr) 2022-08-17
MX2022008490A (es) 2022-10-13
CN114423457A (zh) 2022-04-29
MA57226B1 (fr) 2023-06-28
AU2021205484A1 (en) 2022-08-18
JOP20220168A1 (ar) 2023-01-30
KR20220130151A (ko) 2022-09-26
WO2021142257A1 (fr) 2021-07-15
EP4000624A1 (fr) 2022-05-25
CA3164063A1 (fr) 2021-07-15
BR112022013646A2 (pt) 2022-10-04
JP7771064B2 (ja) 2025-11-17
TN2022000185A1 (en) 2024-04-01
IL294582A (en) 2022-09-01
EP3980069A1 (fr) 2022-04-13
JP2026027353A (ja) 2026-02-18
MA63848B1 (fr) 2024-10-31
MA63848A1 (fr) 2024-04-30
CR20220374A (es) 2023-01-25

Similar Documents

Publication Publication Date Title
MA69153A1 (fr) Méthodes de traitement d'une splénomégalie
MX2022004983A (es) Composiciones de profarmaco y metodos de tratamiento.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12023552741A1 (en) Psilocybin Compositions, Methods Of Making And Methods Of Using The Same
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2020009773A (es) Terapia de combinacion.
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
MX2020011817A (es) Metodos para tratar el linfoma.
WO2022271810A3 (fr) Inhibiteurs de pan-ras peptidyle bicycliques
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
PH12017500392A1 (en) Medical treatments based on anamorelin
NZ801473A (en) Lactam-modified polypeptide compounds
MX2026002367A (es) Composiciones de copolimero de bloque sensibles al ph, micelas, y metodos de uso
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2022007113A (es) Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
PH12021551805A1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2023005156A (es) Composiciones terapeuticas sensibles al ph.
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
PH12022551021A1 (en) Sequential anti-cd19 therapy
CL2025002930A1 (es) Programa de dosificación de un inhibidor de her.2
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
MX2025004758A (es) Compuestos y su uso para el tratamiento de hemoglobinopatias